CM vs CME

The deterministic health profile is concerning, highlighted by a weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial strength. While the company exhibits explosive growth (Earnings +46.6% YoY) and a strong track record of earnings beats, these are countered by a severely bearish technical trend (10/100) and a current price that has already exceeded analyst target prices. The stock trades at a premium to its Graham Number ($89.37) but remains well below its growth-based intrinsic value ($207.09), suggesting a conflict between short-term health risks and long-term growth potential.

CME Group trades near fair value with strong profitability and a dominant market position in financial derivatives, supported by a 58.95% profit margin and 63.39% operating margin—both well above sector averages. However, near-term revenue contraction (-3.0% YoY) and stagnant earnings growth (0.0% YoY) raise concerns about cyclical headwinds, while the P/E of 27.6x is above the sector average of 21.8x, limiting upside. Price momentum remains solid with a 1Y return of +33.3%, but insider selling and a 103.7% payout ratio signal caution. Analysts are unanimous in a 'hold' rating, aligning with our neutral stance given mixed fundamentals and valuation.